The Global Pharmaceuticals Market Strategic Intelligence Suite 2026-2031 combines two full-length strategic research reports -- the Global Pharmaceuticals Manufacturing Market Report (production/supply-side, USD 1.84 trillion in 2025, 7.7% CAGR to USD 2.86 trillion by 2031) and the Global Pharmaceuticals Industry Report (consumption/demand-side, USD 1.66 trillion in 2025, 6.8% CAGR to USD 2.45 trillion by 2031) -- plus a cross-report executive presentation, summary document, and interactive infographic.
Most market research on pharmaceuticals answers one of two distinct questions without making clear which one it's answering: the value of drugs manufactured, or the value of drugs purchased. This Suite is built specifically to close that gap, bundling both reports with cross-report deliverables that compare the two directly, including analysis of the real, quantified USD 185 billion production-consumption gap, regional trade flow imbalances (North America's USD 90 billion deficit, Europe's USD 281 billion surplus), and the GLP-1 category's capacity-constrained growth pattern (24.9% manufacturing CAGR versus 10.2% consumption CAGR).
A reader who needs the full picture -- capacity and demand, supply risk and market opportunity -- gets that integrated view in one purchase rather than needing to independently cross-reference two separately-scoped reports.
Most market research on pharmaceuticals answers one of two distinct questions without making clear which one it's answering: the value of drugs manufactured, or the value of drugs purchased. This Suite is built specifically to close that gap, bundling both reports with cross-report deliverables that compare the two directly, including analysis of the real, quantified USD 185 billion production-consumption gap, regional trade flow imbalances (North America's USD 90 billion deficit, Europe's USD 281 billion surplus), and the GLP-1 category's capacity-constrained growth pattern (24.9% manufacturing CAGR versus 10.2% consumption CAGR).
A reader who needs the full picture -- capacity and demand, supply risk and market opportunity -- gets that integrated view in one purchase rather than needing to independently cross-reference two separately-scoped reports.
Scope of Global Pharmaceuticals Market Strategic Intelligence Suite 2026-2031
- This Suite includes the complete Global Pharmaceuticals Manufacturing Market Strategic Research Report.
- This Suite includes the complete Global Pharmaceuticals Industry Strategic Research Report.
- This Suite includes a 10-slide executive presentation comparing both reports' key findings.
- This Suite includes a cross-report summary document explaining the production-consumption linkage.
- This Suite includes an interactive infographic for board-level and investor-facing use.
- This Suite covers all companies, segments, and regions profiled across both underlying reports.
Who can use the Global Pharmaceuticals Market Strategic Intelligence Suite?
This Suite is ideal for people who need both sides of the pharmaceutical value chain in one integrated resource. Some of the intended users are:- Investors evaluating full value-chain exposure across manufacturing and commercial positioning
- Supply chain executives who also need to understand end-market demand
- CDMOs evaluating capacity investment against real demand growth
- C-level executives requiring comprehensive strategic intelligence for board presentations.
Table of Contents
1. Suite Overview2. Report 1: Global Pharmaceuticals Manufacturing Market (full 13-chapter report)
3. Report 2: Global Pharmaceuticals Industry (full 13-chapter report)
4. Suite Bonus Deliverables (Executive Presentation, Summary Document, Infographic)
Companies Mentioned
- Samsung Biologics
- Lonza
- WuXi Biologics
- (additional integrated innovators and CDMOs -- full list in report)
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer Inc.
- Roche
- Johnson & Johnson
- AstraZeneca
- Novartis
- Sanofi
- Merck & Co.
- GSK
- AbbVie
- Bristol-Myers Squibb
